As of Mar 27
| -0.075 / -2.46%|
The 1 analysts offering 12-month price forecasts for Rosetta Genomics Ltd have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate represents a +34.45% increase from the last price of 2.98.
The current consensus among 1 polled investment analysts is to Hold stock in Rosetta Genomics Ltd. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.